Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Inamoto, Yoshihiro; Petriček, Igor; Burns, Linda; Chhabra, Saurabh; DeFilipp, Zack; Hematti, Peiman; Rovó, Alicia; Schears, Raquel; Shah, Ami; Agrawal, Vaibhav; Ahmed, Aisha; Ahmed, Ibrahim; Ali, Asim; Aljurf, Mahmoud; Alkhateeb, Hassan; Beitinjaneh, Amer; Bhatt, Neel; Buchbinder, Dave; Byrne, Michael; Callander, Natalie; ... (2019). Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone marrow transplantation, 54(5), pp. 648-661. Nature Publishing Group 10.1038/s41409-018-0339-6

[img] Text
Non-GVHD ocular complications.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (985kB)

Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Rovó, Alicia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0268-3369

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

08 Jan 2019 12:28

Last Modified:

05 Dec 2022 15:24

Publisher DOI:

10.1038/s41409-018-0339-6

PubMed ID:

30531955

BORIS DOI:

10.7892/boris.123261

URI:

https://boris.unibe.ch/id/eprint/123261

Actions (login required)

Edit item Edit item
Provide Feedback